Genscript Biotech (HKG:1548) associate Legend Biotech generated about $369 million in net trade sales for its CARVYKTI cancer drug in the first quarter of 2025, according to a Tuesday filing.
CARVYKTI, developed by Nasdaq-listed Legend Biotech in partnership with Johnson & Johnson's Janssen Biotech, is an immunotherapy for the treatment of multiple myeloma.
Shares of Genscript Bio slipped almost 2% in late afternoon trade on Wednesday.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.